Regencell Bioscience Holdings Stock Buy Hold or Sell Recommendation
| RGC Stock | USD 5.91 0.04 0.68% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Regencell Bioscience Holdings is 'Strong Sell'. Macroaxis provides Regencell Bioscience buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding RGC positions.
Check out Regencell Bioscience Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Regencell and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Regencell |
Execute Regencell Bioscience Buy or Sell Advice
The Regencell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Regencell Bioscience Holdings. Macroaxis does not own or have any residual interests in Regencell Bioscience Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Regencell Bioscience's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Regencell Bioscience Trading Alerts and Improvement Suggestions
| Regencell Bioscience generated a negative expected return over the last 90 days | |
| Regencell Bioscience has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (4.36 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Regencell Bioscience has a poor financial position based on the latest SEC disclosures | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Segall Bryant Hamill LLC Sells 44,983 Shares of Regal Rexnord Co. |
Regencell Bioscience Returns Distribution Density
The distribution of Regencell Bioscience's historical returns is an attempt to chart the uncertainty of Regencell Bioscience's future price movements. The chart of the probability distribution of Regencell Bioscience daily returns describes the distribution of returns around its average expected value. We use Regencell Bioscience Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Regencell Bioscience returns is essential to provide solid investment advice for Regencell Bioscience.
| Mean Return | -0.16 | Value At Risk | -10.93 | Potential Upside | 22.58 | Standard Deviation | 9.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Regencell Bioscience historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Regencell Stock Institutional Investors
| Shares | Ubs Group Ag | 2024-06-30 | 312 | Blackrock Inc | 2024-06-30 | 238 | Qube Research & Technologies | 2024-06-30 | 13.0 |
Regencell Bioscience Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 143.7K | (327.6K) | 6.4M | (4.9M) | 1.4M | 1.3M | |
| Free Cash Flow | (844.4K) | (767.3K) | (6.0M) | (5.0M) | (4.0M) | (3.8M) | |
| Net Income | (812.4K) | (1.3M) | (7.6M) | (6.1M) | (4.4M) | (4.1M) | |
| End Period Cash Flow | 387.0K | 59.4K | 6.4M | 1.6M | 3.0M | 2.8M |
Regencell Bioscience Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Regencell Bioscience or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Regencell Bioscience's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Regencell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.06 | |
β | Beta against Dow Jones | -0.91 | |
σ | Overall volatility | 9.57 | |
Ir | Information ratio | -0.03 |
Regencell Bioscience Volatility Alert
Regencell Bioscience Holdings is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regencell Bioscience's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regencell Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Regencell Bioscience Fundamentals Vs Peers
Comparing Regencell Bioscience's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Regencell Bioscience's direct or indirect competition across all of the common fundamentals between Regencell Bioscience and the related equities. This way, we can detect undervalued stocks with similar characteristics as Regencell Bioscience or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Regencell Bioscience's fundamental indicators could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Regencell Bioscience to competition |
| Fundamentals | Regencell Bioscience | Peer Average |
| Return On Equity | -0.43 | -0.31 |
| Return On Asset | -0.28 | -0.14 |
| Current Valuation | 68.51 M | 16.62 B |
| Shares Outstanding | 13.01 M | 571.82 M |
| Shares Owned By Insiders | 88.81 % | 10.09 % |
| Shares Owned By Institutions | 0.19 % | 39.21 % |
| Number Of Shares Shorted | 62.16 K | 4.71 M |
| Price To Earning | 26.21 X | 28.72 X |
| Price To Book | 9.29 X | 9.51 X |
| EBITDA | (3.62 M) | 3.9 B |
| Net Income | (4.36 M) | 570.98 M |
| Cash And Equivalents | 59.41 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 85.74 K | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 13.94 X | 2.16 X |
| Book Value Per Share | 0.63 X | 1.93 K |
| Cash Flow From Operations | (4 M) | 971.22 M |
| Short Ratio | 0.31 X | 4.00 X |
| Earnings Per Share | (0.33) X | 3.12 X |
| Price To Earnings To Growth | 2.15 X | 4.89 X |
| Number Of Employees | 12 | 18.84 K |
| Beta | -0.6 | -0.15 |
| Market Capitalization | 76.39 M | 19.03 B |
| Total Asset | 8.44 M | 29.47 B |
| Retained Earnings | (21.62 M) | 9.33 B |
| Working Capital | 7.92 M | 1.48 B |
| Current Asset | 438.2 M | 9.34 B |
| Current Liabilities | 551.3 M | 7.9 B |
| Five Year Return | 4.37 % | |
| Net Asset | 8.44 M |
Note: Acquisition by Kaplan Stephen A of 10000 shares of Regencell Bioscience at 14.87 subject to Rule 16b-3 [view details]
Regencell Bioscience Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Regencell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Regencell Bioscience Buy or Sell Advice
When is the right time to buy or sell Regencell Bioscience Holdings? Buying financial instruments such as Regencell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Regencell Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Regencell Bioscience Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.